VRIC 2018, Day 2: Notes from the Floor

It’s a wrap for 2018’s Vancouver Resource Investment Conference (VRIC). Held this past Sunday (January 21) and Monday (January 22), the event was the busiest it’s been in years, with more than 8,000 attendees and over 250 exhibitors. If you weren’t able to make it to the two-day show, don’t worry. The Investing News Network (INN) team was on the floor covering talks and panels, speaking with analysts and of course tweeting throughout the day. Click here to see our overview of the first day of the conference, and scroll on to see our recap of day two. And don’t forget to watch out for additional coverage and interviews from the event in the coming weeks. table.inline-text-ad { border-left: none; border-right: none; } .inline-text-ad h1 { font-size: 18px !important; font-weight: bold !important; } .inline-text-ad p { font-size: 1.0rem; } “Start Here – What you need to know to start investing in … Continue reading

Acasti Pharma Announces the Closing of Over-Allotment Option for its Public Offering of Common Shares

Acasti Pharma (NASDAQ:ACST) a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® for the treatment of severe hypertriglyceridemia, today announced that the underwriters of its offering of 9,900,990 common shares, together with warrants to purchase up to 8,910,891 common shares have given notice to exercise their over-allotment option by purchasing an additional 766,179 common shares at a price of US$1.01 per share, for additional gross proceeds to Acasti of approximately US$773,000. As quoted in the press release: The Benchmark Company, LLC is acting as book-running manager of this Offering and as representative of the underwriters, The Benchmark Company, LLC and Dawson James Securities, Inc. Click here to read the full press release. table.inline-text-ad { border-left: none; border-right: none; } .inline-text-ad h1 { font-size: 18px !important; font-weight: bold !important; } .inline-text-ad p { font-size: 1.0rem; } Are You Aware of the FDA’s Plans for … Continue reading

Histogenics Corporation Announces Pricing of Underwritten Registered Direct Offering of 2,340,430 Shares of Common Stock

Histogenics (Nasdaq:HSGX), a leader in the development of restorative cell therapies, today announced the pricing of an underwritten registered direct offering of 2,340,430 shares of its common stock at a price of $2.35 per share. As quoted in the press release: The gross proceeds to Histogenics from this offering are expected to be $5,500,010.50, before deducting underwriting discounts and commissions, and offering expenses payable by Histogenics.  Certain entities affiliated with directors of Histogenics may purchase shares of common stock in the offering at $2.56, today’s closing price of our common stock on The Nasdaq Capital Market. Histogenics intends to use the net proceeds from the offering for working capital and general corporate purposes. Click here to read the full press release. table.inline-text-ad { border-left: none; border-right: none; } .inline-text-ad h1 { font-size: 18px !important; font-weight: bold !important; } .inline-text-ad p { font-size: 1.0rem; } Biotech Stocks in 2018 Find out … Continue reading

ChemoCentryx Announces Positive Overall Survival Results with CCR2 Inhibitor CCX872

ChemoCentryx (Nasdaq:CCXI) announced today positive overall survival results from an ongoing Phase Ib clinical trial of the Company’s second CCR2 inhibitor – CCX872 – in the treatment of locally advanced/metastatic pancreatic cancer. As quoted in the press release: “The positive findings from our pancreatic cancer trial demonstrate that improved patient survival could result from selectively inhibiting CCR2 with CCX872, thereby blocking the immune-suppressing cells that CCR2 maintains in the tumor environment. This is a new approach aimed at liberating the body’s own potential for a powerful anti-tumor immune response,” said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. “These data support CCX872 as a very promising, novel immunotherapeutic approach to treating this deadly form of cancer. Building on these highly encouraging results, we look forward to the opportunity to advance CCX872 in combination with other therapies.” Click here to read the full press release. table.inline-text-ad { border-left: … Continue reading

Ultragenyx Announces Proposed Public Offering of Common Stock

Ultragenyx Pharmaceutical (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it has commenced an underwritten public offering of up to $175,000,000 of shares of its common stock. As quoted in the press release:  In addition, the company is expected to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional $26,250,000 of shares of common stock at the public offering price, less the underwriting discount. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed. J.P. Morgan Securities LLC, BofA Merrill Lynch, Goldman Sachs & Co. LLC and Cowen are acting as joint book-running managers for the offering. Click here to read the full press release. table.inline-text-ad { border-left: none; border-right: none; } .inline-text-ad … Continue reading

AveXis Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

AveXis (NASDAQ:AVXS) today announced the closing of its previously announced underwritten public offering of 4,509,840 shares of its common stock at a price to the public of $102.00 per share before underwriting discounts and commissions, including 588,240 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares. As quoted in the press release: AveXis intends to use its existing cash and cash equivalents and the net proceeds of the offering to fund its research, manufacturing and clinical activities to support its programs in SMA, Rett syndrome and ALS, to fund its pre-commercial activities, including medical affairs, development of commercial initiatives for the potential launch of AVXS-101 and licensing activities, and for general corporate purposes and working capital. Goldman Sachs & Co. LLC, Jefferies LLC and BofA Merrill Lynch acted as joint book-running managers. BMO Capital Markets Corp. acted as lead manager. Click here to read … Continue reading

BeiGene Announces Closing of $800 Million Public Offering

BeiGene (NASDAQ:BGNE) a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced the closing of its follow-on public offering of 7,920,800 American Depositary Shares each representing 13 of its ordinary shares, par value $0.0001 per share, at a price to the public of $101.00 per ADS, for gross proceeds of approximately $800 million before deducting underwriting discounts and commissions and other offering expenses. This includes the full exercise of the underwriters’ option to purchase an additional 495,050 ADSs. As quoted in the press release: BeiGene intends to use proceeds from the offering for working capital and general corporate purposes, including research and development activities. Goldman Sachs & Co. LLC, Morgan Stanley, Cowen, and Leerink Partners acted as joint book-running managers in this offering, and William Blair & Company, L.L.C. acted as co-manager. Click here to read the full … Continue reading

Stemline Therapeutics Announces Proposed Public Offering of Common Stock

Stemline Therapeutics (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, today announced that it intends to offer and sell, subject to market conditions, 3,700,000 shares of its common stock in an underwritten public offering. As quoted in the press release: Stemline intends to use the net proceeds from this offering for (i) clinical, regulatory, manufacturing and, if and when approved, potential commercial activities of SL‑401; (ii) clinical development of SL‑801 and SL‑701; (iii) research and development activities; (iv) potential acquisitions and in-licensing; and (v) other general corporate purposes. Click here to read the full press release. table.inline-text-ad { border-left: none; border-right: none; } .inline-text-ad h1 { font-size: 18px !important; font-weight: bold !important; } .inline-text-ad p { font-size: 1.0rem; } Are You Aware of the FDA’s Plans for 2018? Find out what’s going on in our new report Give me my free report! The post Stemline Therapeutics Announces Proposed Public … Continue reading

Harvard Bioscience To Acquire Data Sciences International and Sells Denville Scientific

Harvard Bioscience (Nasdaq:HBIO) a global developer, manufacturer and marketer of a broad range of solutions to advance life science, has entered into a definitive merger agreement to acquire 100% of the outstanding stock of Data Sciences International, Inc. for approximately $70 million. As quoted in the press release: DSI, a St. Paul, Minnesota-based life science research company, is a recognized leader in physiologic monitoring focused on delivering preclinical products, systems, services and solutions to its customers. Its customers include pharmaceutical and biotechnology companies, as well as contract research organizations, academic labs and government researchers. For the trailing 12 months (“TTM”) ended December 31, 2017, DSI had approximately $44 million in revenue. Click here to read the full press release. table.inline-text-ad { border-left: none; border-right: none; } .inline-text-ad h1 { font-size: 18px !important; font-weight: bold !important; } .inline-text-ad p { font-size: 1.0rem; } Biotech Stocks in 2018 Find out how the … Continue reading

Filo Mining Announces Share Issuance Pursuant to Credit Facility

Filo Mining Corp. (“Filo Mining or the “Company”) (TSXV:FIL) (Nasdaq First North:FIL) (“Filo Mining”, “Filo”, or the “Company”), reports that it has issued 6,000 common shares to Zebra Holdings and Investments S.a.r.l., in consideration of a previously announced US$2,000,000 credit facility, following acceptance of the transaction by the TSX Venture Exchange. The 6,000 issued common shares are subject to a four (4) month hold period ending on May 23, 2018. For further details concerning the terms of the credit facility, please refer to the Company’s news release dated January 12, 2018. ABOUT FILO MINING CORP. Filo Mining’s flagship project is its 100% controlled Filo del Sol Project located on the border between San Juan Province, Argentina and Region III, Chile. Filo del Sol is located between the prolific Maricunga and El Indio Gold Belts, two major mineralized trends that contain such deposits as Caspiche, La Coipa, Veladero, El Indio, and Pascua Lama. The region … Continue reading